Press releases
- Press releases
- Browse
Press releases
SAN DIEGO, CA, November 22, 2010 – Jaleva Pharmaceuticals LLC announces encouraging pre-clinical results for ‘NicoFix’, Jaleva’s proprietary Nicotine Replacement Therapy product currently under development.
BioTox Sciences has completed a pre-c More
BioTox Sciences has completed a pre-c More
Hamburg, December 10th, 2010
Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.
Amarin h More
Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.
Amarin h More
Questcor Signs Agreement With Beacon Pharmaceuticals to Market H.P. Acthar Gel in the United Kingdom
Questcor Pharmaceuticals has signed an agreement with Beacon Pharmaceuticals of Tunbridge Wells, Kent, UK, for the exclusive marketing and distribution of H.P. Acthar(R) Gel in the United Kingdom. More
Norgine and APR, together with its joint venture partner Labtec, today announced that they have entered into an exclusive licensing agreement under which Norgine has acquired the commercialization rights in Europe and selected non-European countries in Mi More
Jaleva Pharmaceuticals LLC is pleased to announce that the FDA has confirmed the regulatory pathway for RelievaDrop, Jaleva’s proprietary transbuccal Nicotine Replacement Therapy (NRT) product currently under development. The FDA confirmed that the pathw More
Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has launched a new version of its CollaRx Gentamicin Surgical Implant that is specially designed for maximum convenience and ease of use in cardiac surgery. More
First part of multi-stage lead generation project, for novel Nitric Oxide synthase inhibitors, now completed More
STOWIC's IP and processes have been acquired by United Pharmaceuticals of Jordan. More
Added value to New Antiepileptic Drug More
First authorities have approved marketing authorization for Desitin's Orfiril solution for injection in the indication More
Related Reports
Market Research Reports provided by reports.iptechex.com
Sep 2011 - 97 pages - $3,500
Oct 2010 - 53 pages - $1,000
Aug 2008 - 110 pages - $1,040
Dec 2008 - 25 pages - $200
Jan 2010 - $75
Jun 2006 - 1068 pages - $2,495
Jul 2011 - 98 pages - $5,700
Jun 2011 - 99 pages - $5,700
Jan 2010 - $75
Jan 2010 - $75
Your selection
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- CNS trauma
- Diabetic neuropathy
- Fibromyalgia
- Muscular dystrophy
- Myasthenia gravis
- Peripheral neuropathy
- Sexual dysfunction
- Smoking cessation
- Year
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us